Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 0.7%

Neoleukin Therapeutics, Inc. (NASDAQ:NLTXGet Free Report) traded down 0.7% during mid-day trading on Thursday . The company traded as low as $37.01 and last traded at $37.47. 48,886 shares were traded during trading, a decline of 2% from the average session volume of 50,104 shares. The stock had previously closed at $37.73.

Neoleukin Therapeutics Price Performance

The stock’s 50-day moving average is $35.18 and its 200-day moving average is $29.64. The stock has a market cap of $352.14 million, a price-to-earnings ratio of -12.05 and a beta of 1.11.

Hedge Funds Weigh In On Neoleukin Therapeutics

A hedge fund recently bought a new stake in Neoleukin Therapeutics stock. Adage Capital Partners GP L.L.C. purchased a new position in shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTXFree Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 310,000 shares of the company’s stock, valued at approximately $1,224,000. Adage Capital Partners GP L.L.C. owned 3.52% of Neoleukin Therapeutics as of its most recent SEC filing. 52.37% of the stock is owned by institutional investors.

About Neoleukin Therapeutics

(Get Free Report)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Further Reading

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.